Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 31 | 2023 | 238 | 8.060 |
Why?
|
| Stroke | 39 | 2023 | 2163 | 5.440 |
Why?
|
| Brain Ischemia | 21 | 2023 | 665 | 4.560 |
Why?
|
| Endovascular Procedures | 14 | 2023 | 366 | 3.520 |
Why?
|
| Complement System Proteins | 8 | 2021 | 135 | 2.920 |
Why?
|
| Intracranial Aneurysm | 4 | 2022 | 87 | 2.120 |
Why?
|
| Complement Activation | 9 | 2021 | 145 | 1.880 |
Why?
|
| Aneurysm, Infected | 2 | 2022 | 16 | 1.460 |
Why?
|
| Patient Selection | 3 | 2019 | 592 | 1.450 |
Why?
|
| Brain Injuries, Traumatic | 3 | 2021 | 105 | 1.370 |
Why?
|
| Complement Inactivating Agents | 4 | 2021 | 56 | 1.350 |
Why?
|
| Synapses | 3 | 2021 | 222 | 1.350 |
Why?
|
| Treatment Outcome | 33 | 2023 | 7029 | 1.340 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 176 | 1.310 |
Why?
|
| Retrospective Studies | 30 | 2023 | 7277 | 1.190 |
Why?
|
| Stents | 5 | 2021 | 657 | 1.170 |
Why?
|
| Pandemics | 5 | 2023 | 352 | 1.120 |
Why?
|
| Recovery of Function | 9 | 2021 | 506 | 1.100 |
Why?
|
| Protein Interaction Maps | 2 | 2015 | 30 | 1.020 |
Why?
|
| Registries | 8 | 2022 | 733 | 1.020 |
Why?
|
| Aneurysm, Ruptured | 2 | 2022 | 40 | 1.010 |
Why?
|
| Regeneration | 2 | 2015 | 105 | 0.980 |
Why?
|
| Aged, 80 and over | 18 | 2022 | 4848 | 0.970 |
Why?
|
| Humans | 66 | 2023 | 68618 | 0.940 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2020 | 105 | 0.930 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2020 | 296 | 0.930 |
Why?
|
| Disease Outbreaks | 3 | 2023 | 83 | 0.900 |
Why?
|
| Catheters | 3 | 2022 | 39 | 0.900 |
Why?
|
| Brain Infarction | 3 | 2020 | 54 | 0.890 |
Why?
|
| Neurosurgery | 2 | 2020 | 42 | 0.880 |
Why?
|
| Aged | 30 | 2022 | 14862 | 0.880 |
Why?
|
| Reperfusion Injury | 4 | 2021 | 320 | 0.870 |
Why?
|
| Fibrinolytic Agents | 5 | 2021 | 377 | 0.830 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 98 | 0.830 |
Why?
|
| Male | 39 | 2022 | 37321 | 0.820 |
Why?
|
| Prospective Studies | 13 | 2022 | 3705 | 0.820 |
Why?
|
| Complement Pathway, Alternative | 3 | 2018 | 69 | 0.800 |
Why?
|
| Hydrocephalus | 4 | 2022 | 40 | 0.790 |
Why?
|
| Inflammation | 2 | 2018 | 1030 | 0.790 |
Why?
|
| Middle Aged | 28 | 2021 | 21147 | 0.730 |
Why?
|
| Proteomics | 4 | 2015 | 246 | 0.730 |
Why?
|
| Aneurysm | 1 | 2020 | 53 | 0.730 |
Why?
|
| Animals | 24 | 2022 | 20881 | 0.730 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 2791 | 0.720 |
Why?
|
| Cerebral Revascularization | 2 | 2020 | 45 | 0.720 |
Why?
|
| Cerebral Veins | 1 | 2019 | 6 | 0.700 |
Why?
|
| Paracentesis | 1 | 2020 | 25 | 0.700 |
Why?
|
| Infusion Pumps | 1 | 2019 | 39 | 0.690 |
Why?
|
| Physicians | 1 | 2023 | 324 | 0.660 |
Why?
|
| Female | 32 | 2022 | 38074 | 0.650 |
Why?
|
| Reperfusion | 6 | 2020 | 78 | 0.640 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 34 | 0.620 |
Why?
|
| Poliovirus Vaccines | 1 | 2017 | 1 | 0.610 |
Why?
|
| Poliomyelitis | 1 | 2017 | 4 | 0.610 |
Why?
|
| Infratentorial Neoplasms | 3 | 2022 | 7 | 0.610 |
Why?
|
| Motor Cortex | 1 | 2019 | 158 | 0.600 |
Why?
|
| Immunization Programs | 1 | 2017 | 25 | 0.600 |
Why?
|
| Mice | 13 | 2022 | 8474 | 0.590 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.580 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 117 | 0.580 |
Why?
|
| Pyramidal Tracts | 1 | 2017 | 45 | 0.580 |
Why?
|
| Microglia | 4 | 2021 | 143 | 0.580 |
Why?
|
| Organ Specificity | 1 | 2016 | 167 | 0.550 |
Why?
|
| Functional Laterality | 1 | 2017 | 240 | 0.540 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 335 | 0.540 |
Why?
|
| Population Surveillance | 1 | 2017 | 285 | 0.530 |
Why?
|
| Gene Targeting | 1 | 2015 | 58 | 0.520 |
Why?
|
| Receptors, Complement 3d | 1 | 2015 | 45 | 0.520 |
Why?
|
| Mechanical Thrombolysis | 3 | 2021 | 29 | 0.520 |
Why?
|
| Neurons | 2 | 2018 | 881 | 0.520 |
Why?
|
| Thromboembolism | 1 | 2016 | 91 | 0.510 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 198 | 0.500 |
Why?
|
| Armed Conflicts | 1 | 2014 | 3 | 0.490 |
Why?
|
| Hepatitis B | 1 | 2015 | 42 | 0.490 |
Why?
|
| Leishmaniasis | 1 | 2014 | 4 | 0.490 |
Why?
|
| Ear, Inner | 1 | 2015 | 47 | 0.490 |
Why?
|
| Liver Failure, Acute | 1 | 2015 | 49 | 0.490 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2550 | 0.480 |
Why?
|
| Immunoglobulin M | 4 | 2021 | 172 | 0.480 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 290 | 0.450 |
Why?
|
| Blood Pressure | 4 | 2020 | 1451 | 0.440 |
Why?
|
| Computational Biology | 1 | 2014 | 190 | 0.410 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2022 | 29 | 0.390 |
Why?
|
| Neuroimmunomodulation | 2 | 2021 | 16 | 0.390 |
Why?
|
| Proteins | 1 | 2015 | 474 | 0.380 |
Why?
|
| Databases, Factual | 5 | 2021 | 622 | 0.350 |
Why?
|
| Thrombolytic Therapy | 6 | 2021 | 233 | 0.350 |
Why?
|
| Phagocytosis | 2 | 2021 | 65 | 0.340 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 551 | 0.320 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 249 | 0.320 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 3259 | 0.300 |
Why?
|
| Refugees | 2 | 2017 | 9 | 0.280 |
Why?
|
| Lebanon | 2 | 2017 | 67 | 0.270 |
Why?
|
| Time Factors | 6 | 2021 | 4655 | 0.260 |
Why?
|
| Neuroprotective Agents | 2 | 2018 | 317 | 0.250 |
Why?
|
| Adult | 9 | 2022 | 21403 | 0.250 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 424 | 0.230 |
Why?
|
| Incidence | 4 | 2022 | 1603 | 0.230 |
Why?
|
| After-Hours Care | 2 | 2020 | 17 | 0.220 |
Why?
|
| Postoperative Complications | 3 | 2020 | 1615 | 0.210 |
Why?
|
| Efficiency | 1 | 2023 | 49 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2022 | 2358 | 0.210 |
Why?
|
| P-Selectin | 1 | 2021 | 16 | 0.200 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 15 | 0.200 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 17 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 17 | 0.200 |
Why?
|
| Receptors, Complement 3b | 1 | 2021 | 35 | 0.200 |
Why?
|
| Hindlimb | 1 | 2021 | 38 | 0.200 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2022 | 61 | 0.200 |
Why?
|
| Carotid Artery, Internal | 1 | 2021 | 85 | 0.190 |
Why?
|
| Nervous System | 1 | 2021 | 45 | 0.190 |
Why?
|
| Spinal Cord Compression | 1 | 2021 | 23 | 0.190 |
Why?
|
| Neurogenesis | 1 | 2021 | 32 | 0.190 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 28 | 0.190 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.190 |
Why?
|
| Nerve Regeneration | 1 | 2021 | 42 | 0.190 |
Why?
|
| Central Nervous System | 1 | 2021 | 107 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 179 | 0.190 |
Why?
|
| Lung Injury | 1 | 2021 | 38 | 0.190 |
Why?
|
| Cell Adhesion | 1 | 2021 | 324 | 0.180 |
Why?
|
| Angioplasty, Balloon | 1 | 2021 | 110 | 0.180 |
Why?
|
| Spinal Fusion | 1 | 2021 | 90 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 95 | 0.180 |
Why?
|
| Lung Transplantation | 1 | 2021 | 88 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2018 | 880 | 0.170 |
Why?
|
| Sheep | 1 | 2019 | 128 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 244 | 0.170 |
Why?
|
| Cerebellum | 1 | 2020 | 103 | 0.170 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 134 | 0.170 |
Why?
|
| Electrodes | 1 | 2019 | 147 | 0.170 |
Why?
|
| Middle Cerebral Artery | 1 | 2019 | 57 | 0.160 |
Why?
|
| Carotid Arteries | 1 | 2019 | 110 | 0.160 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 168 | 0.160 |
Why?
|
| Intracranial Thrombosis | 1 | 2018 | 14 | 0.160 |
Why?
|
| Algorithms | 2 | 2015 | 1196 | 0.160 |
Why?
|
| Mental Disorders | 2 | 2015 | 659 | 0.160 |
Why?
|
| Opsonin Proteins | 1 | 2018 | 4 | 0.160 |
Why?
|
| Complement C3d | 1 | 2018 | 10 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 159 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2021 | 328 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2020 | 183 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2021 | 2007 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 214 | 0.160 |
Why?
|
| Neuroprotection | 1 | 2018 | 28 | 0.150 |
Why?
|
| Syria | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 182 | 0.150 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2018 | 20 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2018 | 63 | 0.150 |
Why?
|
| Hospitalization | 2 | 2021 | 978 | 0.150 |
Why?
|
| Dendrites | 1 | 2018 | 44 | 0.150 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2018 | 63 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2018 | 114 | 0.150 |
Why?
|
| Liver Regeneration | 1 | 2017 | 38 | 0.150 |
Why?
|
| Nerve Degeneration | 1 | 2018 | 134 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 163 | 0.150 |
Why?
|
| Complement C3 | 1 | 2018 | 101 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Cerebral Angiography | 1 | 2018 | 151 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.150 |
Why?
|
| Acute Disease | 1 | 2019 | 658 | 0.140 |
Why?
|
| Pneumonia | 1 | 2018 | 110 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2021 | 2689 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 378 | 0.140 |
Why?
|
| Ischemia | 1 | 2018 | 229 | 0.140 |
Why?
|
| Brain | 2 | 2018 | 2176 | 0.140 |
Why?
|
| Seizures | 1 | 2018 | 279 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 376 | 0.140 |
Why?
|
| Serum | 1 | 2016 | 24 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 24 | 0.130 |
Why?
|
| Young Adult | 2 | 2020 | 5717 | 0.130 |
Why?
|
| Hypertension | 3 | 2020 | 1535 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.130 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 92 | 0.130 |
Why?
|
| United States | 4 | 2023 | 7367 | 0.130 |
Why?
|
| Data Curation | 1 | 2015 | 2 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 1026 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 51 | 0.130 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 14 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2020 | 1692 | 0.130 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 502 | 0.130 |
Why?
|
| Guanine | 1 | 2015 | 21 | 0.130 |
Why?
|
| Logistic Models | 1 | 2019 | 1420 | 0.130 |
Why?
|
| Homeostasis | 1 | 2016 | 291 | 0.120 |
Why?
|
| Sepsis | 1 | 2018 | 233 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2015 | 219 | 0.120 |
Why?
|
| Neurosciences | 1 | 2015 | 15 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2015 | 164 | 0.120 |
Why?
|
| Proteome | 1 | 2015 | 87 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 415 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 236 | 0.120 |
Why?
|
| Estrogens | 1 | 2015 | 173 | 0.120 |
Why?
|
| Warfare | 1 | 2014 | 58 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2017 | 706 | 0.120 |
Why?
|
| Systems Biology | 1 | 2014 | 25 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1851 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2014 | 109 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2015 | 211 | 0.110 |
Why?
|
| Genomics | 1 | 2014 | 168 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2014 | 111 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 1593 | 0.100 |
Why?
|
| Protein Binding | 1 | 2015 | 1027 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 2093 | 0.100 |
Why?
|
| Europe | 2 | 2021 | 196 | 0.100 |
Why?
|
| Blood Pressure Determination | 2 | 2019 | 152 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2021 | 384 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2014 | 2455 | 0.080 |
Why?
|
| Infant | 1 | 2014 | 2891 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2014 | 3187 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2022 | 2083 | 0.070 |
Why?
|
| Risk Factors | 3 | 2021 | 5731 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1465 | 0.060 |
Why?
|
| Child | 1 | 2014 | 6405 | 0.060 |
Why?
|
| Cytidine Triphosphate | 1 | 2022 | 3 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 109 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 131 | 0.050 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2022 | 7 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2324 | 0.050 |
Why?
|
| Adolescent | 1 | 2014 | 8912 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 59 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 168 | 0.050 |
Why?
|
| Epidural Space | 1 | 2021 | 15 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 37 | 0.050 |
Why?
|
| North America | 1 | 2021 | 112 | 0.050 |
Why?
|
| Drainage | 1 | 2021 | 133 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 55 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2022 | 396 | 0.050 |
Why?
|
| Maze Learning | 1 | 2021 | 138 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2021 | 85 | 0.050 |
Why?
|
| Neuroendoscopy | 1 | 2020 | 4 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2021 | 156 | 0.050 |
Why?
|
| Internationality | 1 | 2021 | 74 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 532 | 0.050 |
Why?
|
| Vertebral Artery | 1 | 2020 | 22 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2020 | 60 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 161 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 64 | 0.040 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 169 | 0.040 |
Why?
|
| Complement Pathway, Classical | 1 | 2020 | 22 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 2020 | 86 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 100 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 110 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 99 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 65 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 239 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 266 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 242 | 0.040 |
Why?
|
| Leukemia | 1 | 2020 | 117 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.040 |
Why?
|
| Expectorants | 1 | 2018 | 5 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2018 | 27 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 465 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 521 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 384 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Autophagy | 1 | 2020 | 208 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 80 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 458 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 137 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2020 | 201 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 245 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 157 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2018 | 418 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1664 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 866 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 329 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 848 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2017 | 400 | 0.030 |
Why?
|
| Biological Science Disciplines | 1 | 2014 | 2 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 64 | 0.030 |
Why?
|
| Rats | 1 | 2022 | 5300 | 0.030 |
Why?
|
| Biosensing Techniques | 1 | 2014 | 51 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 2014 | 50 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1641 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.030 |
Why?
|
| Nanostructures | 1 | 2014 | 112 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 186 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1753 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 1667 | 0.010 |
Why?
|